Burkhard F. Leeb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Burkhard F. Leeb has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Bernhard Rintelen
Second Department of Medicine, Center for Rheumatology, State Hospital Stockerau, Stockerau, Austria; Karl Landsteiner Institute for Clinical Rheumatology, Stockerau, Austria
4 shared publications- Bernhard Rintelen
2nd Dept. of Medicine, Center for Rheumatology Lower Austria, Karl Landsteiner Institute for Clinical Rheumatology, State Hospital Stockerau, Austria
4 shared publications Judith Sautner
Department of Medicine, Center for Rheumatology, Lower Austria, State Hospital Stockerau, Karl Landsteiner-Institute for Clinical Rheumatology, Landstrasse 18, A-2000 Stockerau, Austria
4 shared publications- Thomas Nothnagl
Department of Medicine II, Centre for Rheumatology, Stockerau State Hospital, Stockerau, Austria
3 shared publications Adil Maktari
2 shared publications- Bernhard Rintelen
Lower Austrian State Hospital Stockerau, 2nd Department for internal medicine, Lower Austrian Center for Rheumatology, Landstrasse 18, Stockerau, 2000, Austria.
2 shared publications
Latest Publications
- 8 July 2017
- Published by Springer Nature
- p. 113-119
Biologicals: A Perspective for the Treatment of PMR/GCA
- 8 July 2017
- Published by Springer Nature
- p. 113-119
Biologicals: A Perspective for the Treatment of PMR/GCA
- 8 July 2017
- Published by Springer Nature
- p. 121-131
Monitoring Tools for Polymyalgia Rheumatica/Giant Cell Arteritis
- 8 July 2017
- Published by Springer Nature
- p. 121-131
Monitoring Tools for Polymyalgia Rheumatica/Giant Cell Arteritis
- Open Access
- 27 January 2017
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 4, 6
The Short Form Score for the Assessment and Quantification of Chronic Rheumatic Affections of the Hands in Daily Clinical Routines—Its Sensitivity to Change and Preliminary Patient Relevant Variation Values: A Pilot Study
Objective: The SF-SACRAH was developed to assess hand involvement in rheumatoid arthritis (RA) and hand osteoarthritis (HOA) patients in daily clinical routine. In this pilot study its sensitivity to change should be assessed longitudinally, and preliminary thresholds for patient relevant changes should be figured out. Methods: Ninety-nine out patients suffering from HOA (n = 55) or RA (n = 44) completed the SF-SACRAH once and after approximately 3 months and patients rated their satisfaction (PATSAT) with the disease state (1 = very good to 5 = unsatisfactory) simultaneously. For assessing its sensibility to change, SF-SACRAH changes in patients stable, improving or worsening according to PATSAT were calculated in HOA as well as in RA patients. The respective medians, but also the highest values were taken to estimate patient relevant variation values. SF-SACRAH changes and PATSAT changes to the better or worse in HOA as well as RA patients were analyzed applying the Kruskal Wallis test., In RA patients the DAS28 was additionally calculated. For correlation of SF-SACRAH changes to the EULAR response criteria, Spearman’s rho was calculated. Results: In HOA as well as in RA patients a highly statistically correlation between PATSAT-changes and SF-SACRAH values could be revealed (p 0.6: ΔSF-SACRAH -0.4, ΔDAS28 0.6: ΔSF-SACRAH +0.5). Correlation of SF-SACRAH changes according to the EULAR response criteria was moderate. Conclusion: The SF-SACRAH constitutes a reliable tool for hand impairment assessment in chronic rheumatic diseases and proved to be sensitive to change in this short term evaluation in HOA as well as in RA patients. Additionally, preliminary patient variation values for improvement (-1.60) and worsening (+1.0) could be figured out.
- 27 January 2017
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 4, 6
Open AccessThe Short Form Score for the Assessment and Quantification of Chronic Rheumatic Affections of the Hands in Daily Clinical Routines—Its Sensitivity to Change and Preliminary Patient Relevant Variation Values: A Pilot Study
Objective: The SF-SACRAH was developed to assess hand involvement in rheumatoid arthritis (RA) and hand osteoarthritis (HOA) patients in daily clinical routine. In this pilot study its sensitivity to change should be assessed longitudinally, and preliminary thresholds for patient relevant changes should be figured out. Methods: Ninety-nine out patients suffering from HOA (n = 55) or RA (n = 44) completed the SF-SACRAH once and after approximately 3 months and patients rated their satisfaction (PATSAT) with the disease state (1 = very good to 5 = unsatisfactory) simultaneously. For assessing its sensibility to change, SF-SACRAH changes in patients stable, improving or worsening according to PATSAT were calculated in HOA as well as in RA patients. The respective medians, but also the highest values were taken to estimate patient relevant variation values. SF-SACRAH changes and PATSAT changes to the better or worse in HOA as well as RA patients were analyzed applying the Kruskal Wallis test., In RA patients the DAS28 was additionally calculated. For correlation of SF-SACRAH changes to the EULAR response criteria, Spearman’s rho was calculated. Results: In HOA as well as in RA patients a highly statistically correlation between PATSAT-changes and SF-SACRAH values could be revealed (p 0.6: ΔSF-SACRAH -0.4, ΔDAS28 0.6: ΔSF-SACRAH +0.5). Correlation of SF-SACRAH changes according to the EULAR response criteria was moderate. Conclusion: The SF-SACRAH constitutes a reliable tool for hand impairment assessment in chronic rheumatic diseases and proved to be sensitive to change in this short term evaluation in HOA as well as in RA patients. Additionally, preliminary patient variation values for improvement (-1.60) and worsening (+1.0) could be figured out.
- 24 October 2016
- Published by Springer Nature in rheuma plus
- Vol. 15 (4) , 87
Weg vom Mittelwert
- 18 October 2016
- Vol. 34
RADAI-5 and electronic monitoring tools.
Tighter monitoring of patients is regarded one of the key approaches to improve management of rheumatoid arthritis (RA). It could be demonstrated that the patient relevant disease course is not simply the linear link between two observation points, but fluctuates significantly in up to 80% of patients surveyed three times over two months, which understandably compromises quality of life. Patient self-report questionnaires such as the Rheumatoid Arthritis Disease Activity Index-Five (RADAI-5) have been shown to provide reliable information about disease activity, functionality, and other important aspects of daily life. The internal consistency of such questionnaires was shown to be significantly higher than the one of the DAS28 or the CDAI. Innovative electronic tools can be easily foreseen to constitute the media to enhance the dialogue between healthcare professionals and patients to improve disease care. These tools collect patient-recorded outcomes (PROs) data, through which physicians can monitor the course of the individual disease. Electronic versions can enable patients to receive additional medical attention between visits and provide a more detailed record of disease course over time. Applying the RADAI-5 or other questionnaires in electronic assessment tools will allow for the individual assessment of health levels, well-being, joint pain and the quality of life. Such tools will enable more frequent patient monitoring, with the potential to improve the patient's situation as well as to enhance physicians' time management, and to prioritise patients who may need further attention.
- 18 October 2016
- Vol. 34
RADAI-5 and electronic monitoring tools.
Tighter monitoring of patients is regarded one of the key approaches to improve management of rheumatoid arthritis (RA). It could be demonstrated that the patient relevant disease course is not simply the linear link between two observation points, but fluctuates significantly in up to 80% of patients surveyed three times over two months, which understandably compromises quality of life. Patient self-report questionnaires such as the Rheumatoid Arthritis Disease Activity Index-Five (RADAI-5) have been shown to provide reliable information about disease activity, functionality, and other important aspects of daily life. The internal consistency of such questionnaires was shown to be significantly higher than the one of the DAS28 or the CDAI. Innovative electronic tools can be easily foreseen to constitute the media to enhance the dialogue between healthcare professionals and patients to improve disease care. These tools collect patient-recorded outcomes (PROs) data, through which physicians can monitor the course of the individual disease. Electronic versions can enable patients to receive additional medical attention between visits and provide a more detailed record of disease course over time. Applying the RADAI-5 or other questionnaires in electronic assessment tools will allow for the individual assessment of health levels, well-being, joint pain and the quality of life. Such tools will enable more frequent patient monitoring, with the potential to improve the patient's situation as well as to enhance physicians' time management, and to prioritise patients who may need further attention.
- Open Access
- 26 August 2016
- Published by Springer Nature in rheuma plus
- Vol. 15 (3) , 51
Ganzheitlicher Therapieansatz
- 26 August 2016
- Published by Springer Nature in rheuma plus
- Vol. 15 (3) , 51
Open AccessGanzheitlicher Therapieansatz
- Open Access
- 22 August 2016
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 17 (1) , 358
Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria
The purpose of the present study was to check the validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology, and to elucidate eventual differences with respect to disease activity (DA) in patients with rheumatoid arthritis (RA) on established biological DMARDs (bDMARDs) before inclusion into the register (EST) and beginners at the time point of inclusion (NEW) after 1 year of treatment. RA patients with a complete follow-up of 1 year in BIOREG were divided into EST and NEW and compared with respect to DA, remission rates, concomitant synthetic DMARDs (csDMARDs) and glucocorticoid therapy (GC) at baseline and after 1-year follow-up. Safety concerns are listed. Descriptive statistics are applied. For 346 RA patients (284 EST, 62 NEW) out of 970 RA patients included into BIOREG, a full data set for a 1-year follow-up was available. No differences in DA were observed after 1 year as expressed by DAS28 or RADAI-5, and small differences as expressed by remission rates according to DAS28, RADAI-5 or Boolean criteria (namely approximately 1/2, 1/3 to 1/4 and 1/4 to 1/5 of the patients respectively). Sixty-four adverse events (AEs) were noted in 56 (20 %) of EST and 20 in 19 (31 %) of NEW patients. Malignancy occurred in four patients. After 1 year, 48 % of EST patients but only 16 % of NEW patients were on bDMARD monotherapy. Regarding DA, the date collected in BIOREG appeared to be valid. After 1 year of bDMARD therapy, all patients, whether EST or NEW, achieved a similar level of DA. AEs occurred more frequently during the early phase of bDMARD treatment. Austrian rheumatologists initiate bDMARD therapy in patients with lower disease levels than in other European countries, leading to high remission rates.
- 22 August 2016
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 17 (1) , 358
Open AccessValidity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria
The purpose of the present study was to check the validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology, and to elucidate eventual differences with respect to disease activity (DA) in patients with rheumatoid arthritis (RA) on established biological DMARDs (bDMARDs) before inclusion into the register (EST) and beginners at the time point of inclusion (NEW) after 1 year of treatment. RA patients with a complete follow-up of 1 year in BIOREG were divided into EST and NEW and compared with respect to DA, remission rates, concomitant synthetic DMARDs (csDMARDs) and glucocorticoid therapy (GC) at baseline and after 1-year follow-up. Safety concerns are listed. Descriptive statistics are applied. For 346 RA patients (284 EST, 62 NEW) out of 970 RA patients included into BIOREG, a full data set for a 1-year follow-up was available. No differences in DA were observed after 1 year as expressed by DAS28 or RADAI-5, and small differences as expressed by remission rates according to DAS28, RADAI-5 or Boolean criteria (namely approximately 1/2, 1/3 to 1/4 and 1/4 to 1/5 of the patients respectively). Sixty-four adverse events (AEs) were noted in 56 (20 %) of EST and 20 in 19 (31 %) of NEW patients. Malignancy occurred in four patients. After 1 year, 48 % of EST patients but only 16 % of NEW patients were on bDMARD monotherapy. Regarding DA, the date collected in BIOREG appeared to be valid. After 1 year of bDMARD therapy, all patients, whether EST or NEW, achieved a similar level of DA. AEs occurred more frequently during the early phase of bDMARD treatment. Austrian rheumatologists initiate bDMARD therapy in patients with lower disease levels than in other European countries, leading to high remission rates.
- 21 June 2016
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 55 (11) , 1919-1920
Should physicians’ consider patient perception for modulating treatment?
- 21 June 2016
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 55 (11) , 1919-1920
Should physicians’ consider patient perception for modulating treatment?
- 3 June 2016
- Published by Springer Nature in rheuma plus
- Vol. 15 (2) , 23
Es wird wieder spannend in der Rheumatologie
- 3 June 2016
- Published by Springer Nature in rheuma plus
- Vol. 15 (2) , 23
Es wird wieder spannend in der Rheumatologie